Overview

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Status:
Recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.

Phase:

Phase 1

Details

Lead Sponsor:

Astex Pharmaceuticals, Inc.

Treatments:

Decitabine